Abstract 1504TiP
Background
For patients (pts) with EGFR-mutant NSCLC, upfront treatment with tyrosine kinase inhibitors is standard. Drug resistance remains a challenge and an effective therapy after progression is needed. Ivonescimab (SMT112/AK112) is a novel bispecific antibody that provides dual blockade of PD-1 and VEGF activity. And coengagement of these 2 targets increases affinity to PD-1 by more than 10 fold. Given the correlation between VEGF-A and PD-1 expression in the tumor microenvironment, simultaneous blockade of these 2 targets by ivonescimab may produce enhanced antitumor activity, with an improved safety profile, compared to co-administration of individual anti-PD-(L)1 and an anti-VEGF agents. Phase 2 trial data reported that in 19 pts with EGFR mutated NSCLC who progressed following TKI therapy, the response rate to ivonescimab plus pemetrexed and carboplatin was of 68.4% (13/19) and a tolerable safety profile in the total population (N=83) treated with ivonescimab plus chemotherapy.
Trial design
HARMONi is a randomized, double-blind, multiregional phase 3 trial of ivonescimab or placebo in combination with pemetrexed and carboplatin in pts with locally advanced or metastatic EGFR-mutant NSCLC. 470 pts will be randomized 1:1 and to receive ivonescimab/placebo plus pemetrexed and carboplatin (Q3W, 4 cycles, 21 days per cycle) followed by ivonescimab/placebo plus pemetrexed for maintenance therapy for up to 2 yrs until progression or unacceptable toxicity. The co-primary endpoints are overall survival and progression-free survival assessed by IRC per RECIST v1.1. Secondary endpoints include overall response rate, incidence/severity of adverse events and immunogenicity of ivonescimab. Key eligibility criteria include advanced or metastatic NSq- NSCLC with an activating EGFR mutation, Eastern Cooperative Oncology Group Performance Status 0 or 1 and progression on/following third generation EGFR-TKI. The study will be a multi-national study including United States, Cana, Euroadpe and China.
Clinical trial identification
NCT05184712.
Editorial acknowledgement
Legal entity responsible for the study
Summit Therapeutics and Akeso Biopharma.
Funding
Summit Therapeutics and Akeso Biopharma.
Disclosure
F. Cappuzzo: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, BMS, Pfizer, Takeda, Lilly, Bayer, Amgen, Sanofi, PharmaMar, Mirati, Novocure, Ose, and MSD; Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, BMS, Pfizer, Takeda, Lilly, Bayer, Amgen, Sanofi, Mirati, PharmaMar, Novocure, Ose, Galecto and MSD. J.W. Goldman: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Advisory Board: Genentech, Eli Lilly, Janssen, AbbVie, Gritstone; Financial Interests, Institutional, Coordinating PI: AstraZeneca, Eli Lilly; Financial Interests, Institutional, Local PI: Genentech, Janssen, BMS, AbbVie. J. Remon Masip: Financial Interests, Personal, Invited Speaker: Roche, MSD, Boehringer Ingelheim; Financial Interests, Personal, Writing Engagement: Pfizer; Financial Interests, Personal, Advisory Board: AstraZeneca, Ose Immunotherapeutics, BMS, Janssen, Takeda, Sanofi; Financial Interests, Institutional, Invited Speaker: Merck Portugal; Non-Financial Interests, Principal Investigator, PI of PECATI trial in Thymic malignancies endorsed by a grant by MSD: MSD; Non-Financial Interests, Other, Co-PI of APPLE trial (EORTC-1525): AstraZeneca; Non-Financial Interests, Member, Secretary of the Lung Cancer Group at the EORTC: EORTC. W. Li, M. Xia: Financial Interests, Personal, Full or part-time Employment: Akeso. J. Li, D. James, L. Styles: Financial Interests, Personal, Full or part-time Employment: Summit Therapeutics; Financial Interests, Personal, Stocks/Shares: Summit Therapeutics. H.L. West: Financial Interests, Personal, Advisory Role: Summit Therapeutics. L. Zhang: Financial Interests, Institutional, Research Grant, research grant & Trial Chair: AZ; Financial Interests, Institutional, Research Grant: BMS, Roche; Financial Interests, Institutional, Trial Chair: QiLu pharm, Henrui Pharm, Novartis, Hansoh Pharma, China Shiyao Pharma, Kelun Pharm. All other authors have declared no conflicts of interest.
Resources from the same session
1543P - Clinical study of camrelizumab combined with docetaxel and carboplatin in neoadjuvant treatment of locally advanced oesophageal squamous cell carcinoma
Presenter: Rui Wang
Session: Poster session 21
1544P - Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of advanced gastric/gastroesophageal junction cancer: A phase II clinical trial
Presenter: Xin fang Hou
Session: Poster session 21
1545P - Phase II trial of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus
Presenter: Yuexiao Qi
Session: Poster session 21
1546P - Safety, efficacy, and biomarkers for ONO-4578 plus nivolumab in unresectable advanced or recurrent gastric or gastroesophageal cancer
Presenter: Hidekazu Hirano
Session: Poster session 21
1547P - SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarkers for nivolumab in gastric cancer
Presenter: Chiaki Inagaki
Session: Poster session 21
1549P - A prospective study of circulating tumor DNA (ctDNA) genomic profiling in gastric or gastroesophageal junction (GEJ) cancer patients with recurrence after adjuvant chemotherapy: Liquid-GEAR trial
Presenter: Hiroyuki Takeda
Session: Poster session 21
1551P - Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric cancer
Presenter: Choong-kun Lee
Session: Poster session 21
1552P - Clinical multi-omics analysis of gastric cancer (GC) in Europe (EU) and Latin America (LatAm): The LEGACy project
Presenter: Tania Fleitas
Session: Poster session 21
1553P - Blood-borne assessment of stromal activation in esophageal adenocarcinoma to guide tocilizumab therapy: A randomized phase II proof-of-concept study
Presenter: Benthe Doeve
Session: Poster session 21